Interventional cardiology includes heart diagnostics and non-surgical therapeutics such as catheter-based procedures and the use of minimally-invasive instruments and devices to restore healthy blood flow to the heart, repair or replace damaged or failing heart valves, reverse dangerous conditions such as congestive heart failure, reduce risk of heart attacks and strokes, save limbs, eliminate pain and improve mobility. Diagnostic interventional cardiology includes coronary angiogram to determine any blockage to arteries and intravascular ultrasound (IVUS) to evaluate a heart’s arteries. Minimally-invasive heart surgery and treatment consists of cardiac catheterization to diagnose or treat certain heart conditions, angioplasty and stent placement (percutaneous coronary intervention or PCI) to restore healthy blood flow to the heart, carotid angioplasty and stenting (CAS) to open narrowed or blocked carotid arteries, angioplasty and stent placement to open narrowed or blocked peripheral arteries, rotational atherectomy to remove calcified lesions from arteries, percutaneous balloon valvuloplasty to open a narrowed or blocked heart valve, transcatheter aortic valve replacement (TAVR/TAVI) to replace an aortic valve, also as an alternative to open-heart surgery for high-risk patients, and adult heart structural procedures to treat congenital heart defects such as aortic valve stenosis, atrial septal defect, ventricular septal defect, or pulmonary valve stenosis and other adult congenital heart defects. The U.S. market for interventional cardiology devices is driven by the population at risk of developing angina or suffering from myocardial infarction, which encompasses men over 45 or women over 55 years of age.
The global interventional cardiology diagnostic and therapeutic devices market segmentation is based on diagnostic devices (coronary angiography, intravascular ultrasound, guidewire-based physiologic, intravascular stenosis assessment, optical coherence tomography, intracardiac echocardiography), therapeutic devices type (coronary stent systems, percutaneous transluminal coronary angioplasty devices, coronary atherectomy systems – laser atherectomy systems, mechanical atherectomy systems, transcatheter septal defect repair devices, coronary thrombectomy systems).
The global interventional cardiology diagnostic and therapeutic devices market research report provides market size (Revenue US$ Million 2014 to 2021), procedure volumes, market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global interventional cardiology diagnostic and therapeutic devices market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global interventional cardiology diagnostic and therapeutic devices market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global interventional cardiology diagnostic and therapeutic devices market and profiled in this report include Abbott Laboratories, Inc., B. Braun Melsungen AG, Bayer AG, Boston Scientific Corporation, BVM Medical Ltd., Cardiovascular Systems Inc., Cook Medical, Inc., C.R. Bard, Inc., Edwards Lifesciences, Getinge Group, iVascular, Johnson & Johnson (Cordis Corporation/ Cardinal Health, Inc.), Kyoto Medical Planning Corporation Ltd., Lepu Medical Technology, Medtronic, Inc., Merit Medical Systems, Inc., Siemens AG, Smiths Medical, Spectranetics Corp., Terumo Corporation, Vascular Solutions, Inc., and W. L. Gore & Associates.